• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Authors » Noah Capurso, MD

Articles by Noah Capurso, MD

Research Update

Intravenous Buprenorphine Microinduction

May 29, 2023
Noah Capurso, MD and Marissa Bayerl, APRN
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Marissa Bayerl, APRN, and Noah Capurso, MD, MHS. Ms. Bayerl and Dr. Capurso have no financial relationships with companies related to this material.

Buprenorphine microinduction can be a useful method of starting BUP induction, however it is not always feasible, particularly in the hospital setting. Here, we discuss the development of an intravenous microinduction protocol that could provide an alternative to the usual sublingual and transdermal routes of administration. 


Read More
Clinical Update

Fentanyl Testing: An Emerging Harm Reduction Strategy

May 29, 2023
Noah Capurso, MD and Alyssa Falleni, PharmD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Alyssa Falleni, PharmD. CT Health Education and Research in SUD and Related Harms (CHERISH) Fellow; VA Connecticut Healthcare System, Orange, CT.

Noah Capurso, MD, MHS. Assistant Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief of The Carlat Addiction Treatment Report.

Dr. Falleni and Dr. Capurso have no financial relationships with companies related to this material.

Discover the lifesaving potential of fentanyl test strips (FTS). As fentanyl infiltrates illicit drug markets, FTS offer an essential harm reduction strategy. We’ll explore the technology behind FTS, how to obtain and use them, discuss their legality, and examine their role in preventing opioid overdose deaths. 


Read More
Clinical Update

Gabapentin: A Double-Edged Sword

April 1, 2023
Noah Capurso, MD and Shram Shukla, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Shram Shukla, MD. Addiction psychiatry fellow, Yale School of Medicine. New Haven, CT.

Noah Capurso, MD, MHS. Assistant professor of psychiatry, Yale University. New Haven, CT. Editor-in-chief of The Carlat Addiction Treatment Report.

Dr. Shukla and Dr. Capurso have no financial relationships with companies related to this material.

Gabapentin has become one of the most widely prescribed medications in America. At the same time, concerns have emerged about its association with opioid overdose deaths. In this article, we review the data behind gabapentin treatment: when it should be used, how to use it, and when it should be avoided.


Read More

E-Cigarettes and Relapse to Cigarette Smoking

July 1, 2022
Noah Capurso, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Noah Capurso, MD. Dr. Capurso, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Evidence for the use of e-cigarettes as smoking cessation agents continues to evolve. In this observational study, researchers find that e-cigarettes modestly increase the risk of relapse to smoking in patients who have managed to quit.


Read More

Buprenorphine Treatment

November 5, 2021
Noah Capurso, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Noah Capurso, MDNoah Capurso, MD

Assistant Professor of Psychiatry at Yale University, CT. Editor-in-chief of The Carlat Addiction Treatment Report.

Dr. Capurso has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Buprenorphine is a first line medication for the treatment of opioid use disorder yet remains vastly under-prescribed. Here, Dr. Capurso reviews the pharmacologic principles relevant to buprenorphine prescribing and lays out how to start patients on the medication both in the clinic and at home.
Read More

A New High-Dose Naloxone: Life Saver or Punishment?

July 3, 2021
Noah Capurso, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Noah Capurso, Editor-in-ChiefNoah Capurso, MD 

Dr. Capurso has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.


The FDA recently approved a nasal spray formulation of naloxone. Called Kloxxado, each spray delivers 8mg, twice as much as the most widely used formulation, Narcan. Whether or not this higher dose is necessary, is debatable.
Read More
Previous 1 2 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.